The National Quality Forum has endorsed a minimum of 12 lymph node (LN) as a surrogate measure of quality in colorectal cancer (CRC). The prognostic value of ultrastaging hematoxylin and eosin (H&E) negative LNs (N0) using pan-cytokeratin immunohistochemistry (pan-CK-IHC) is unknown. Purpose: To assess the effect on survival of surgical quality and focused pathologic analysis. Patients and Methods: Between 2001 and 2007, 253 evaluable patients with resectable CRC were enrolled. Multiple sectioning and pan-CK-IHC were performed on N0 LNs (American Joint Commission on Cancer Stage II). Follow-up was performed at 6-month intervals with a 4-year disease-free survival (DFS) primary end-point. Results: There were 253 patients, 177 N0 and 76 N1/N2 patients, staged conventionally. Thirty-six (20%) N0 patients were upstaged using ultrastaging (N03 N0iϩ ͓n ϭ 27͔ and N03 N1mi ͓n ϭ 9͔). At a mean follow-up of 3.4 Ϯ 1.6 years, 38 (15%) have recurred. Only 3% (3/108) of patients with Ն12 LNs, negative by H&E and pan-CK-IHC (N0iϪ), compared with 18% (6/33) with Ͻ12 LNs/N0iϪ (6/33; P ϭ 0.0015) have recurred. Four-year DFS differed significantly according to surgical quality (Ͻ12 vs. Ն12 LNs) among Stage II patients only (DFS, Ͻ12 vs. Ն12 LNs: Stage I, 90.5% vs. 97.7%, P ϭ 0.22; Stage II, 67.5% vs. 94.7%, P ϭ 0.0036; Stage III, 61% vs. 61%, P ϭ 0.61). Conclusion: This represents the first prospective report demonstrating that both surgical quality and nodal ultrastaging impacts survival in Stage II CRC. Patients with Stage II CRC having Ն12 LNs negative for micrometastases (N0iϪ) are likely cured by surgery alone. Both surgical and pathologic quality measures are imperative in early CRC to improve patient selection for adjuvant chemotherapy.
C olorectal cancer (CRC) is the third most frequently diagnosed cancer and the second leading cause of cancer mortality in the United States. 1 Within the American Joint Commission on Cancer (AJCC) staging system regional nodal tumor dissemination in the absence of distant metastasis differentiates Stage III from Stage I/II disease. 2 In fact, the staging of CRC as well as the decision to use adjuvant systemic therapy to a great extent relies on the tumor status of the regional lymph nodes (LNs). 3 In patients with nonmetastatic disease, regional nodal dissemination is a principal determinant of cancer outcomes. Importantly, the number of mesenteric nodes removed surgically as well as the number of nodes assessed pathologically governs not only accuracy of tumor staging, but also overall survival. 4 -6 The unacceptably high rate of disease recurrence in patients undergoing surgical resection of apparently LN-negative (N0) disease is attributable, in part, to incomplete resection of tumor-bearing regional LNs, possible stage migration (the Will Rogers Phenomenon) and under-treatment (failing to treat understaged patients with systemic therapy). 2, 5, 7 There is wide variation in number of LNs retrieved surgically from patients with CRC. In a large populationbased analysis in the United States we found that the median number of mesenteric LNs resected at time of colectomy in patients with colon cancer (CC) was 9 and the mode was zero. 4 Consensus-driven quality improvement initiatives in cancer care have emerged as a result of this and other studies pointing to unacceptably low nodal yield from surgical specimens. These multidisciplinary, evidencebased practice management and quality improvement efforts involve the National Cancer Institute and Veteran Health Affairs (Cancer Care Outcomes Research and Surveillance), the American Society of Clinical Oncology, RAND/Harvard and Commission on Cancer (CoC) of the American College of Surgeons (ACS), National Initiative on Cancer Care Quality, National Quality Forum (NQF), and National Comprehensive Cancer Network. The ACS CoC submitted consensus standards for the diagnosis and treatment of CRC to the NQF, which through collaboration with American Society of Clinical Oncology and National Comprehensive Cancer Network developed 2 agreed upon national consensus quality standards for CRC: (1) Ն12 LNs removed surgically and examined pathologically for resected CC; and (2) adjuvant systemic therapy considered or administered within 120 days of diagnosis for patients less than age 80 with AJCC Stage III disease. 8 -11 Understaging may also reflect tumor biology as well as the inherent limitations of conventional pathologic nodal assessment in detecting low volume disease: Ͻ1% of any given LN is assessed morphologically by standard hematoxylin-eosin (H&E) microscopy resulting in sampling error. 4, 12, 13 These undetected micrometastases (MM) may account for the high (20%-30%) rate of disease recurrence after surgical resection of Stage II CC. 14, 15 The clinical relevance of MM detected by pan-cytokeratin immunohistochemistry (pan-CK-IHC) found to be negative by H&E staining in patients with CC 16 have not, however, been uniformly accepted. Our group has demonstrated the utility of ultrastaging with nodal step sections and pan-CK-IHC for the detection of occult nodal disease, and has underscored the potential prognostic impact of MM in our ongoing efforts to not only standardize the surgical and pathologic evaluation, but also improve patient selection for adjuvant therapy for Stage II CC. 14, 15, 17, 18 The present analysis of 2 international prospective trials was undertaken to assess the impact of surgical quality and nodal ultrastaging on long-term disease-free survival (DFS) in early CRC.
METHODS

Specific Aims
We aimed to assess the effect on DFS of: (1) surgical quality (Ͻ12 vs. 12 or more nodes resected surgically and assessed pathologically); and, (2) focused pathologic assessment (step section and pan-CK-IHC detected presence or absence of MM disease among AJCC Stage II: N0iϪ vs. N0iϩ) in enrolled study subjects with nonmetastatic (AJCC Stage I-III) adenocarcinoma of the colon and rectum. A well-characterized cohort with long-term follow-up derived from 2 prospective observational trials of targeted nodal assessment in CRC was used for analysis. This study represents the work of a clinical research consortium including the United States Military Cancer Institute, Cancer Centers within the United States, Europe, and Israel.
Primary End Point
The primary outcome variable in this study was 4-year DFS. DFS was defined as time from study enrollment to the first documentation of disease recurrence or death.
Study Population
A total of 253 patients provided written informed consent and were enrolled over a 6-year study period in 2 prospective multicenter clinical trials of LN ultrastaging in CRC. 14, 17 Eligibility criteria have been previously described. 14, 17 In brief, study subjects were adults (age, 18 years or older) with potentially curable primary nonmetastatic colon (n ϭ 217) or rectal (n ϭ 36) carcinoma detected by endoscopy. Patients were considered noneligible if they were found to have metastatic disease intraoperatively or failed to meet the major eligibility criteria. Patients with CRC were followed at 6-month interval for 4 years postoperatively. Colonoscopy was obtained 1 and 4 years after surgery and a chest radiograph and computed tomography scan of the abdomen and pelvis annually. An analysis of pooled data was then performed. Institutional Review Board approval for this study was provided by University of California, Los Angeles, California (09 -09 -088 -01) and Hadassah Medical Organization, Jerusalem (16 -28 -03-03).
Surgical Technique and Pathologic Nodal Assessment
Surgeons enrolling patients in these trials were experienced surgical oncologists and colorectal surgeons that have demonstrated technical competence and perform at least 20 CRC surgeries a year. An oncologic resection was performed to include all regional mesenteric LNs. Standard histopathologic examination was performed on the resected colon and/or rectal specimen as well as the surrounding LNs. Ultrastaging of the H&E negative LNs by pan-CK-IHC was performed as previously described. 14, 17 Serial step sectioning at 40 to 200 micrometer intervals was conducted on formalin-fixed-paraffin embedded LNs. Four 4-micrometer sections were stained with H&E (first, second, third, and fourth sections) and 2 (second and fourth sections) were evaluated with pan-CK-IHC. The avidin-biotin-peroxidase complex method was used for the IHC according to a standardized protocol (Pankeratin AE1/AE3, CAM 5.2, 35bH11; Ventana Medical Systems, Tucson, AZ). 14, 17, 19 For isolated tumor cells (ITCs) or cell clusters (CCs) within the LNs evaluated with pan-CK-IHC to be considered positive, the following 2 criteria had to be met: (1) cells had to stain strongly positive; and (2) cells had to demonstrate anatomic and cytologic features of carcinoma. A pan-CK-IHC-positive node was defined as a LN containing single cells or cell clusters (largest cluster, Յ0.2 mm) demonstrating morphologic features consistent with CRC apparent on evaluation of H&E and/or pan-CK-IHC stained sections of the node. Tumor deposits within LNs were classified and staged according to the revised guidelines set by the AJCC (2002, 6th edition) and International Union Against Cancer. 20, 21 The largest LN cluster of cohesive aggregates of carcinoma cells was measured. Metastases less than 2 mm and greater than 0.2 mm (Ͼ0.2-Ͻ2 mm) were considered MM (N1mi); isolated tumor cells or cell clusters up to 0.2 mm (Յ0.2 mm) were usually detected by IHC ( Fig. 1 ) and classified (N0iϩ). Rare single cells staining positive with IHC that lacked cytologic characteristics of malignancy were considered tumor-negative (N0iϪ).
Statistical Analysis
All data were reviewed and analyzed by the Department of Biostatistics at UCLA (D.E.) and the Department of Clinical Investigation, Division of Biostatistics, Walter Reed Army Medical Center (R.H.). Summary statistics were obtained using established methods. The categorical variables were compared between groups using Fisher exact test or 2 test as appropriate. Continuous data are presented as means and standard deviations (mean Ϯ SD) and were compared using the 2-sample t test. If assumptions for normality were not satisfied (determined by the Shapiro-Wilk test) then data were summarized using the median and range and groups were compared using the Wilcoxon rank sum test. All tumor staging was conducted according to the AJCC TNM Staging (2002, 6th edition) criteria. The mean, median, and mode of the number of LNs examined were determined. On the basis of the national guidelines, analysis was stratified by those with 12 or more, and those with fewer than 12 nodes resected surgically and examined pathologically, and in conventionally staged N0 (AJCC Stage I/II patients) stratified according to IHC results: N0(iϪ) (H&E͓Ϫ͔/pan-CK-IHC ͓Ϫ͔) versus N0(iϩ) (H&E͓Ϫ͔/pan-CK-IHC ͓ϩ͔).
Demographic and clinical factors associated with surgical resection of 12 or more nodes were examined in a multivariate model using logistic regression. Variables which had a P Յ 0.20 in the univariate analysis were entered into the model. The final model included those variables that were significant at the P Ͻ 0.05 level and are presented with odds ratio together with 95% confidence intervals.
The primary outcome variable in this study was DFS, which was defined as time from study enrollment to the first documentation of disease recurrence or death as a result of any cause, whichever came first. DFS analysis was undertaken using the Kaplan-Meier method. Survival differences were analyzed using the Log-rank test. A Cox proportional hazards model was used for multivariate analysis. Factors potentially significant (P Ͻ 0.05) on univariate analysis were entered into the multivariate model. The models were obtained by starting with all significant factors (univariate P Ͻ 0.05) in the model and removing, stepwise, factors that were not significant in the multivariate analysis. Therefore, a hierarchical forward stepwise methodology was used to screen clinical/pathologic variables for model inclusion. Separate models were created for those with Ն12, and those with Ͻ12 LNs. We included variables at a significance level of P Ͻ 0.05. Statistical analysis was performed using SPSS v17.0 (SPSS Inc, Chicago IL). Significance levels were set at P Ͻ 0.05. All tests were 2-sided.
RESULTS
Clinical and Pathologic Characteristics
Of the 253 evaluable patients, 135 were female (53%) and 118 male (47%), with a median age of 71 years. Baseline demographic and clinical characteristics of the entire study population are shown in Table 1 . Mean body mass index (BMI) for the study population was 25.7 Ϯ 4.4 kg/m 2 and more than half of the patients were either overweight (38%; BMI, Ն25.0 -29.9 kg/m 2 ) or obese (15%; BMI, Ն30 kg/m 2 ). Most tumors were of colonic origin. Primary tumors were located in the colon in 217 (86%) patients and in the rectum in 36 (14%) patients.
The majority of patients (93%) underwent open segmental resection of the colon. Types of resection performed included the following: right colectomy (n ϭ 114; 45%), sigmoid colectomy (n ϭ 50; 20%), low anterior resection (n ϭ 37; 14%), total colectomy (n ϭ 25; 10%), left colectomy (n ϭ 22; 9%), transverse colectomy (n ϭ 3; 1%), total proctocolectomy (n ϭ 1; Ͻ1%), and APR (1; Ͻ1%).
More than 70% of tumors invaded through the muscularis propria and into the subserosa, pericolonic tissues, or adjacent organs (AJCC T3 or T4). Median primary tumor size was 3.6 cm and more than 80% of tumors were of intermediate (67%) or high (16%) histologic grade. Microscopically apparent lymphovascular invasion was identified in 11% of primary tumors.
The mean number of LNs staged was 20 Ϯ 12. Over 80% (205/253) of patients had 12 or more LNs resected surgically and evaluated pathologically, and a third (76/253; 30%) were nodepositive (AJCC N1 ͓n ϭ 50͔ or N2 ͓n ϭ 26͔; Figure 2 ) by conventional histopathology (H&E). Mean number of resected and mean number of positive nodes identified according to surgical quality indicator, Ͻ12 versus Ն12 nodes were as follows: resected, 8.0 (Ͻ12 nodes) versus 22.0 (Ն12 nodes); and mean number of positive nodes, 0.6 (Ͻ12 nodes) versus 2.0 (Ն12 nodes). By multivariate logistic regression analysis (Table 2) , only primary tumor size (P ϭ 0.01) and tumor location (colon vs. rectum) (P ϭ 0.013) were associated with increased LN retrieval (Ն12 LNs).
Of the 177 H&E node-negative (AJCC N0 by conventional staging) patients, 27 (15%) were found to have IHC-positive ITCs in ultra-staged nodes (N0 3 N0iϩ) Figure 2 . Most (21/27; 78%) of these patients had T3 tumors. A majority of these upstaged patients did not have lymphovascular invasion (23/27; 85%) identified in the primary tumor.
Of the 177 H&E node-negative (AJCC N0 by conventional staging) patients, 9 (5%) were found to have MM by ultrastaging (N03 N1mi). Hence, 9 (11%) of the overall 85 node-positive patients (AJCC N1 or N2) were upstaged by nodal step sectioning and pan-CK-IHC from H&E N0 to nodal MM (N03 N1mi) ( Fig. 2 ). Most (7/9; 78%) of these patients had T3 or T4 tumors and none had lymphovascular invasion apparent on microscopic assessment of the primary tumor. The distribution of nodal disease volume is shown in Table 1 , where ITCs or MM were identified in 14% (36/253) of patients with nodal ultrastaging. Therefore, 20% (36/177) overall upstaging (N03 Niϩ ͓n ϭ 27͔ and N03 N1mi ͓n ϭ 9͔; Figure 2 ) was conferred by detailed nodal assessment (step section3 H&E and pan-CK-IHC). (Table 5 ). Disease recurrence varied significantly according to nodal disease volume: N0iϪ: 6% (9/141); N0iϩ: 7% (2/27); N1mi: 22% (2/9); N1/2: 33% (25/76); P Ͻ 0.001 (Table 6 ; Fig. 3 ). Hence, the finding of ITCs and cell clusters (Յ0.2 mm) in LNs by nodal ultrastaging with pan-CK-IHC in otherwise conventionally staged N0 patients did not have an effect on DFS: disease recurrence, N0iϪ versus N0iϩ: 9/141 (6%) versus 2/27 (7%); P ϭ 0.92. However, 26% of patients with N0iϩ received adjuvant chemotherapy versus 11% of N0iϪ who did not (P ϭ 0.054). In the N1/N2 group (Stage III), most (92%) patients were treated with adjuvant chemotherapy (Table 3 ). In the rectal cancer group, 17/36 (47%) patients were treated with neoadjuvant radiation therapy.
Follow-up and Disease-Free Survival
When recurrence according to nodal disease volume was assessed on a site-specific (colon vs. rectum) basis, the same finding of disease recurrence varying significantly with nodal disease volume was demonstrated in the colon (P Ͻ 0.001), but not the rectal cancer population, although the latter subset was certainly small ( Table 6 ). Disease recurrence between patients found to be nodenegative by step section and pan-CK IHC (N0iϪ) was 6% (9/141) Table 5 . A significant difference in rate of disease recurrence was identified among patients with negative nodal ultrastaging (AJCC N0iϪ: H&E ͓Ϫ͔/pan-CK-IHC ͓Ϫ͔) according to surgical quality or nodal yield for the entire group ( Fig. 4) as well as the colon-only study population. By multivariate analysis LN number (Ն12/Ͻ12) and LN status interaction effect (N0iϪ: H&E͓Ϫ͔/pan-CK-IHC͓Ϫ͔ vs. other groups) were independent significant factors (P ϭ 0.01), Table 7 .
DISCUSSION
This study addresses an imperative in CC-that of improving the accuracy of nodal pathologic assessment, recognizing that this assessment is critical to disease staging and treatment planning. The present analysis of 2 international prospective trials was undertaken to assess the impact of surgical quality (Ͻ12 vs. Ն12 nodes) and nodal ultrastaging (step section3 H&E and pan-CK-IHC) on DFS in early CRC. DFS differed significantly according to surgical quality in this study among AJCC Stage II patients, emphasizing that both surgical and pathologic quality measures are critical in early CRC to facilitate judicious adjuvant treatment decisions.
The incidence of node-negative (N0) CRC is increasing in the United States because of improved public awareness and greater access to screening colonoscopy, which enables earlier detection of disease. Despite this, up to one-third of patients recur, possibly because of inadequate lymphadenectomy or inaccurate standard pathologic staging techniques leading to overlooked nodal metastases. This has resulted in considerable debate about the utility of adjuvant chemotherapy in Stage II CC. In a recent review of 37 randomized trials and 11 meta-analyses in over 20,000 patients 22 with AJCC Stage II (N0) CC, there was a 5% to 10% improvement in DFS with adjuvant chemotherapy, but this did not translate into a statistically significant improvement in overall survival. Within these trials, however, there were certain subsets of patients with survival similar to Stage III (node-positive, N1/N2) CC. These largely represented patients with incomplete surgical resection and/or pathologic assessment (Ͻ12 nodes). This is further supported by pooled analyses of data from randomized trials, 23, 24 which demonstrated a strong correlation between survival and number of LNs examined independent of other known prognostic factors. In a large Intergroup Trial analysis (INT 0089), an improvement in 5-year survival from 73% to 87% was reported in Stage II CC when the number of LNs recovered increased from Ͻ10 to Ͼ20, 6 a larger impact than any adjuvant treatment has attained to date.
Both the AJCC and the International Union Against Cancer recommend the examination of at least 12 LNs per specimen, 20, 21 and this has been endorsed nationally as a benchmark for hospitalbased performance. 25, 26 The ACS CoC endorses the NQF consensus standard for CRC: surgical retrieval and pathologic evaluation of Ն12 LNs. This does not, however, address inconsistencies in pathologic evaluation, LN sampling errors in the face of small nodal disease deposits, and the significant limitations of conventional H&E to detect occult nodal metastases.
This analysis of 2 prospective trials was performed to evaluate whether surgical quality (Ն12 LNs) and focused pathologic analysis using multiple nodal sectioning and pan-CK-IHC improves the detection of occult metastases and impacts 4-year DFS. Overall, 36 of 177 patients (20%) were found to have nodal MM (N03 N1mi, n ϭ 9) and ITCs (N03 N0iϩ, n ϭ 27), which were not detected by conventional (H&E) staging methods (Fig. 2) . Nine of 85 (11%) Stage III patients were upstaged with nodal ultrastaging from N0 to N1mi, potentially impacting adjuvant therapy decisions. The 4-year DFS was significantly higher (95%) in Stage II patients with Ն12 nodes compared with Ͻ12 nodes (68%). Only 3% of N0 patients with Ն12 LNs, negative by both H&E and pan-CK-IHC have recurred compared with 18% with Ͻ12 LNs and N0i. Nodal yield did not impact survival in Stage III CC in this study.
CC recurrence varied significantly according to nodal disease volume ( Table 5 , Fig. 3 ), but the finding of ITCs and cell clusters (Յ0.2 mm) alone detected by pan-CK-IHC (N0iϩ) did not impact recurrence; however, these patients were twice as likely to receive adjuvant systemic therapy compared with N0iϪ patients. However, when surgical quality (Ն12 LNs) was combined with pathologic ultrastaging (step section3 H&E and pan-CK-IHC: H&E ͓Ϫ͔/ IHC͓Ϫ͔: N0iϪ), there was a significant improvement in DFS among node-negative (N0) patients ( Table 6 , Fig. 4 ). These data suggest that patients who meet the 12-node minimum benchmark, and are (Table 7) , and will not benefit from adjuvant chemotherapy; however the effect of ultrastaging on Stage III CC is less apparent. This raises several important questions. Does the improvement in survival reflect Stage migration (ie, the "Will Rogers" phenomenon), the response to adjuvant systemic therapy in those patients that are upstaged with nodal ultrastaging, the resection of MM (suggesting MM have prognostic value), better surgery alone, or a combination thereof? Stage migration suggests that the higher the number of nodes examined the greater the chance of finding positive LNs, thereby improving the selection of patients for adjuvant systemic chemotherapy. In a series of 35,787 cases of Stage II CC from the National Cancer Data Base, the 5-year survival for Stage II patients was 64% if only 1 or 2 LNs were examined versus 86% if more than 25 LNs were examined. 27 The National Cancer Data Base investigators concluded that at least 13 LNs should be retrieved and declared negative for an accurate diagnosis of Stage II disease to be attained. In our review of the Surveillance, Epidemiology, and End Results database in more than 82,896 patients treated between 1988 and 2000, the 5-year survival in Stage II CC was 78% when Ն15 nodes were evaluated compared with 70% for 8 to 14 nodes and 66% for 1 to 7 nodes (P Ͻ 0.001). For all CC stages, increased nodal sampling was associated with improved survival. 4 The resection of at least 15 LNs was associated with significantly prolonged median overall survival by 11 months in patients with Stage I disease, by 54 months in Stage II, and by 21 months in Stage III disease. Interestingly, in our prospective trial LN number did not effect survival in Stage III CC. This may reflect that the majority of patients received more effective oxaliplatin-based chemotherapy, which was not available during the data collection period of the Surveillance, Epidemiology, and End Results review, where adjuvant therapy was largely 5-Fluorouracil and Leucovorin, or it may reflect limited sample size on which the analysis was based.
The potential prognostic value of nodal MM detected by ultrastaging in N0 (by conventional H&E) CC remains unresolved. In the current study ITCs detected by pan-CK-IHC failed to significantly impact 4-year DFS in patients with LNs otherwise staged negative by conventional pathologic evaluation (H&E). This may be a consequence of moderate sample size and associated lack of statistical power, or the influence of nodal MM alone (ITCs) on decisions regarding the administration of adjuvant chemotherapy. In this study, treating physicians were not blinded to the pathology reports and this likely reflects the number of N0 patients with ITCs (N0iϩ) who subsequently received adjuvant chemotherapy. Even though no clear benefit of chemotherapy has been demonstrated in this setting, this group may be among those who derive benefit from adjuvant therapy.
Alternatively, tumor cells detected by IHC may not be as prognostically relevant as those detected by molecular assays including quantitative reverse transcription-polymerase chain reaction assay. The prognostic value of micrometastatic lymphatic disease was evaluated in a meta-analysis of all N0 CC between 1991 and 2002 28 that reported overall survival. All studies identified MM after subjecting N0 LNs (by H&E) to greater pathologic scrutiny. Molecular techniques using reverse transcription-polymerase chain reaction upstaged 37% of patients from N0 to N0molϩ and were associated with an absolute survival difference at 3 years of 19%. Overall survival at 3 years was 78% for patients with molecularly detected MM N0molϩ and 97% for patients without molecularly detected MM (N0molϪ; P Ͻ 0.001). Histologic techniques including serial sectioning with IHC staining upstaged 32% of pN0 patients (N0 3 N0iϩ). Although MM identified with IHC techniques appeared to adversely affect survival, the differences were not statistically significant, possibly due to variations in IHC techniques. These variations included differences in the nodal counts per specimen, nodal sections analyzed with IHC per specimen, volume of nodal analysis, the range of anticytokeratin antibodies used and the different definitions used to describe MM.
Changes in the AJCC sixth addition Cancer Staging Manual 20 and the identification of MM in the sentinel node(s) from patients with melanoma and breast cancer have provided standardized terminology that has decreased technical variations in pathologic assessment among subsequent studies. Although the sentinel node concept has been effectively applied to CRC 17, 19 it will largely remain investigational until the biologic relevance of MM has been definitively established. After this is established, targeted nodal assessment in CRC may ultimately prove to be a sensitive, expedient, and cost-effective technique for the evaluation of nodal MM.
Primary tumor characteristics in addition to nodal evaluation are also an essential component in establishing a prognostic profile and predicting disease behavior. The presence of primary satellite tumor deposits has been associated with higher incidence of metastatic recurrence and therefore was recently incorporated into the revised AJCC seventh edition as N1c disease. 29 Intratumoral molecular profiling and specific gene signatures (18q loss of heterozygosity, DNA microsatellite instability (MSI), p27, KRAS mutation, and thymidylate synthase) may prove to be associated with patient prognosis or response to therapy independent of nodal status. 30 -32 Although these factors may become part of a more comprehensive staging system, LN evaluation continues to be the most important prognostic factor, and clinical decision determinant in CC. For this reason, it is imperative for the surgeon to apply oncologic principles to optimize nodal yield and for the pathologist to use techniques to improve the identification of smaller LNs and nodal tumor deposits-MM. Continued emphasis must be placed on standardizing the pathologic and surgical evaluation of patients with N0 CRC. Whether examining a larger number of LNs with ultrastaging techniques minimizes the false-negative results associated with standard H&E assessment and improves staging and prognosis remains to be determined. This study represents the first prospective trial to confirm that the "12 lymph node benchmark" is an important prognostic factor in N0 CC and that patients who meet this quality measure and have LNs negative for MM are likely cured by surgery alone. Our ongoing international prospective multicenter trial (2RO1CA090848) will establish a prognostic profile combining molecular signatures and nodal ultrastaging in Stage II CC. Patients in this trial will not receive adjuvant chemotherapy and that will allow us to further improve risk stratification and provide individualized clinical decision support.
Discussions
DR. MICHAEL STAMOS (ORANGE, CA): This study confirms, for the first time with good prospective data, the importance of the number of LNs identified and presumably the number of LNs resected at the time of operation. Not easily or likely explained solely by the "Will Rogers effect" or stage shifting.
You ultrastaged, if you would, your LNs by step sectioning. You then did H&E staining as well as IHC staining of those LNs, but you did not seem to report those 2 elements separately. At least my pathologists would be delighted to know, are both important or can they skip 1 of those 2 steps, because the time and expense of the pathologist is perhaps equally important to our own time and expense.
For the patients with less than 12 LNs, which was only 20% of your group, arguably a smaller group, it looks like factors other than surgical or pathology quality may have played a role in the low LN yield, for example, gender or BMI. In these patients, what value or role did this ultrastaging have? In other words, one could surmise that these techniques could make up for bad surgery or bad pathology in terms of at least identifying the true Stage II patients. Do you have any data to support or refute this possibility?
You also saw a very widespread between the patients who had more than 12 nodes and those with less than 12 nodes, in terms of the mean number of nodes at least. Was there a bimodal spread or was this just a statistical aberrancy created by a few patients with perhaps 1 or 2 nodes?
Finally, you had 2 aims in this study. I think you demonstrated the importance of the number of LNs, but do you think you proved that ultrastaging or IHC has value above and beyond the finding of greater than 12 LNs? DR. PHILIP PATY (NEW YORK, NY): My question boils down to 2 things: The relatively small number of patients in the trial, and the fact that you are not really powered to look at other variables important to Stage II, such as T stage, lymphovascular invasion, and most importantly, MSI status.
In our work at Memorial Sloan-Kettering, Stage II MSI patients are at least 25% of that population. They have a greater than 95% survival rate from surgery alone, and the MSI patients in general are right-sided and they tend to have statistically significantly more LNs in the mesentery due to a robust host response, which has been correlated to favorable outcomes.
Have you looked at MSI status in your favorable group? Could you actually be selecting for MSI patients in a more expensive way rather than simply by immunohistochemical stage?
Finally, will your follow-up study be powered to look at multivariable analysis in these node-negative patients?
DR. NEIL HYMAN (BURLINGTON, VT): Perhaps I misunderstood your data, but it appeared that the primary prognostic factor was what others have observed, which is that there is an association between more negative nodes and good prognosis. It does not really look like the IHC added very much.
In addition, as you noted, the relationship between the number of nodes and prognosis is strictly an association, and we need to be very careful in attributing causation. We have found no improvement in survival if the operation is performed by a surgeon who achieves higher node counts or in hospitals that tend to report more nodes in colectomy specimens. In other words, high-node hospitals and high-node surgeons do not perform better than low-node surgeons and low-node hospitals with respect to cure rates. Is it possible that your observed associations are related to the patient's immune status or the immunogenicity of the tumor, rather than representing a legitimate quality measure? DR. RICK GREENE (CHARLOTTE, NC): In the new AJCC Cancer Staging Manual, seventh Edition, the T4 category has been divided into T4a and T4b. This was made to make a new Stage IIC, which is defined as T4bN0. Most probably this IIC stage should indicate use of adjuvant chemotherapy. Have you had an opportunity to look at isolated tumor cells in those T4bN0 patients in which the colonic tumor extended into another abdominal organ but the nodes remain negative on H&E microscopic evaluation? DR. MICHAEL CHOTI (BALTIMORE, MD): As you know, there is considerable interest in a variety of prognostic as well as predictive biomarkers, both in colorectal and other cancers. Tumors can be tested, such as with MSI, BRAF, and Oncotype DX profiling. Serum or plasma biomarkers are also being developed and tested, including circulating tumor cells and circulating tumor DNA. Here, you focus on looking at the LN, ultrastaging of the LN as a biomarker, if you will. Can you comment on why you think the answer is in the study of the LNs rather than these other approaches?
My second question relates to the interesting observation that in these ultrastaged patients, when node-negative, ultrastaging did not have prognostic implications. In fact, in the patients who were N0iϩ, the recurrence rate was lower than for those who were N0iϪ.
You mentioned that the adjuvant therapy use was almost 3 times higher in those who were IHC positive. Obviously, the ultrastaging information was divulged to the treating physicians. I am surprised that this was done. Can you comment on the impact of the study results as well as the ethical implications?
Finally, I have a comment on your use of "surgical quality" as it relates to nodal assessment. While perhaps the node count may reflect in aggregate the quality of an institution, there are biologic and other factors that impact on the number of nodes assessed. I would take some issue with the use of the term "surgical quality" in this context. DR. ANTON BILCHIK (SANTA MONICA, CA): This is the first prospective validation of the importance of LN yield in terms of number of nodes resected surgically and evaluated pathologically in early CC. The endorsement of the 12-node minimum by the ACS and the NQF certainly caught the attention of most surgeons and, I suspect, pathologists as well. This is evidenced by a dramatic increase in LN retrieval nationwide.
Dr. Stamos asked whether both H&E analysis and IHC is necessary for ultrastaging LNs. We did not look at this independently because after LN dissection, IHC evaluation is often used as a guide to find MM by H&E that are often missed by H&E slide evaluation alone and were originally missed in this study as well. Painstaking search for an occult metastasis by multiple sectioning and H&E alone is likely to take longer and is cost-prohibitive.
In answer to the next question, concerning the value of ultrastaging in patients with less than 12 LNs, patients in this group tended to be older with a smaller primary tumor size and an earlier T stage. There was also a greater proportion of segmental colon resections that may have contributed to this. According to multivariate analysis, neither gender nor BMI significantly impacted nodal yield.
In patients with 12 or more LNs, ITCs alone did not impact DFS. However, these patients were twice as likely to receive adjuvant chemotherapy, despite a lack of data to support this. Therefore, the potential prognostic role of ITCs in the 12ϩ LN group remains unclear.
With regard to open versus laparoscopic resection, there was an increase in laparoscopy in the United States toward the latter part of the study, but surgeons in Israel (a large accruing site) continue to prefer an open approach.
